Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 3NCT03683186A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionUnited Therapeutics · PAHEnrolling by invitationUTHRLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05300451Daratumumab in HLA Desensitization Prior to TransplantationBarry A. Boilson · Cardiac TransplantEnrolling by invitationJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06419179Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide...University of Cologne · Small Cell Lung CarcinomaEnrolling by invitationAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Sep 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07910422Intradiscal Ozone/Oxygen Injection for Treatment of Contained Lumbar Disc HerniationBeam Research, Inc. · Lumbar Disc HerniationEnrolling by invitationBEAMLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT04682145Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa PegolNovo Nordisk A/S · Haemophilia AEnrolling by invitationNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06794359Minimally Invasive Coronary Artery Bypass Surgery in Patients With Multi Vessel Coronary DiseaseUniversity of Sao Paulo General Hospital · Coronary Arterial Disease (CAD)Enrolling by invitationMDTCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07653139Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in GermanyNovo Nordisk A/S · Haemophilia AEnrolling by invitationNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 26, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05588284Preservation of Venous Valvular Function After PMT for Acute DVTShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Acute Deep Venous Thrombosis of Femoral Vein (Disorder)Enrolling by invitationBSXCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT01982890Telomeres and T-cell Receptor Excision Circles (TRECs) From Peripheral Blood in Normal Subjects Over TimeUniversité de Sherbrooke · Telomere Length in Healthy ControlsEnrolling by invitationJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 28, 2025Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT04945317ROSE for Improved Molecular Marker Testing Via EBUSJohns Hopkins University · Non-small Cell Lung Cancer (NSCLC)Enrolling by invitationAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06109935Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where...Novo Nordisk A/S · Growth Hormone Deficiency in ChildrenEnrolling by invitationNVOLead
- Enrollment
- Locked
- Primary completion
- Jul 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06138743Study of SRP-1003 in Participants With Type 1 Myotonic DystrophySarepta Therapeutics, Inc. · Myotonic Dystrophy 1Enrolling by invitationSRPTLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06374264Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum DisorderMedRhythms, Inc. · Neuromyelitis Optica Spectrum DisorderEnrolling by invitationAZNCollaborator
- Enrollment
- Locked
- Primary completion
- Sep 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06603935Harnessing Digital Medicine to Improve Allergic Rhinitis Management in Primary Care (DMAR)QHSLab, Inc. · Allergic RhinitisEnrolling by invitationUSAQLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2025Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06688838Effective Treatment of Jak1/3 Inhibitor in Blau SyndromeTongji Hospital · Blau SyndromeEnrolling by invitationPFECollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06989281Evaluation of a Primary Care Based Lifestyle Medicine Clinic at UABUniversity of Alabama at Birmingham · Obesity and Obesity-related Medical ConditionsEnrolling by invitationLLYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07713901Database Linkage Study to Evaluate the Risk of Medullary Thyroid CarcinomaNovo Nordisk A/S · Medullary Thyroid CarcinomaEnrolling by invitationNVOLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06443463Long-term Safety and Tolerability of BHV-7000Biohaven Therapeutics Ltd. · Focal EpilepsyEnrolling by invitationBHVNLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT06873035An Interventional Study of Infigratinib in Children With HypochondroplasiaQED Therapeutics, a BridgeBio company · HypochondroplasiaEnrolling by invitationBBIOLead
- Enrollment
- Locked
- Primary completion
- Jan 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06960655Improving Lipid Optimization Quality and Treatment Options in ASCVDBrigham and Women's Hospital · HypercholesterolemiaEnrolling by invitationMRKCollaborator
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 20 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.